Lupin’s arm launches Generic Trizivir Tablets

18 Dec 2013 Evaluate

Pharma Major Lupin’s  US subsidiary-Lupin Pharmaceuticals Inc. has launched  Abacavir Sulfate, Lamivudine, and Zidovudine Tablets, 300mg (base) / 150mg / 300mg in the US after the US District Court for the District of Delaware ruled that the Lupin’s generic version of Trizivir did not infringe on patents. Lupin had earlier received approval for the same.

Lupin’s Abacavir Sulfate, Lamivudine Zidovudine 300mg (Base)/150mg/300mg Tablets are the AB?rated generic equivalent of ViiV Healthcare’s (ViiV) Trizivir Tablets, 300mg (base) / 150mg / 300mg and are indicated in combination with other antiretrovirals or alone for the treatment of HIV?1 infection. Lupin is the first applicant to file an ANDA for Trizivir Tablets and as such is entitled to 180 days of marketing exclusivity.

Trizivir Tablets, 300mg (base) / 150mg / 300mg had annual U.S sales of approximately $ 111.6 million (IMS MAT Sep, 2013).

Lupin Share Price

1603.55 -12.10 (-0.75%)
28-May-2024 15:47 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1464.85
Dr. Reddys Lab 5955.65
Cipla 1477.15
Zydus Lifesciences 1050.35
Lupin 1603.55
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.